Marc Dall'era, MD
Urology · San Francisco, CANPI 1326134859
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.2%), education and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Intuitive Surgical at 42.7% of the total. Reporting peaked in 2019 at $7,632 and has fallen 53.7% since, to $3,531 in 2025.
Across 27 payments — averaging $471.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- EDAP Technomed Inc$3K
- Photocure Inc$3K
- Johnson & Johnson$255
- Urogen Pharma, Inc.$199
- Janssen Scientific Affairs, LLC$120
- plus $141 from 2 others
Across 119 payments — averaging $11,806 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$857K
- Pfizer$503K
- Medivation LLC.$45K
What the payments were for
- Consulting fees$5,50043%
- Travel & lodging$2,95923%
- Food & beverage$1,1779%
- Education$3,09624%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $5,440 |
| EDAP Technomed Inc | 6 | $3,362 |
| Photocure Inc | 5 | $3,215 |
| Johnson & Johnson | 3 | $255 |
| Urogen Pharma, Inc. | 1 | $199 |
| Janssen Scientific Affairs, LLC | 1 | $120 |
| Astellas Pharma US Inc | 2 | $106 |
| AstraZeneca | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,335
- FOCAL ONE$3,296
- Cysview$3,021
- ZUSDURI$199
- ZYTIGA$120
How this compares
$12,732 in reported general payments places this provider in the 80th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 194 | $3,516 |
| Finasteride | 57 | $1,173 |
| Solifenacin Succinate | 28 | $981 |
| Oxybutynin Chloride ErOxybutynin Chloride | 31 | $811 |
| Tadalafil | 33 | $621 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $503 |
| Terazosin Hcl | 14 | $370 |
| Cephalexin | 54 | $60 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $43 |
Paid to pharmacies, not to this prescriber.
Other urology in San Francisco
- Marshall StollerSan Francisco$290K
- Matthew CooperbergSan Francisco$86K
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.